Table 2 Cost data
From: Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?
Item | Proportion | Value | Source |
|---|---|---|---|
Consultation of office-based physicians | 42 € | EBM 2011 codes 3110 and 4110 [48] | |
Outpatient medication | 5 € | Dimenhydrinate and paracetamol, taking into account reductions due to patient co-payments and mandatory rebates [49] | |
Hospitalisation | 1 675 € | G-DRG-System 2011 [50] | |
Hospital stay for 1 parent (children aged <8 years) | 45 €/day | [51] | |
Nosocomial cases | 439 € | G-DRG-System 2011 [50] | |
SHI-reimbursed productivity loss | 78 €/day | 70% of average salary for women (aged 20–35 years) [52] | |
Proportion of families with productivity loss (both parents working) | 31% | Average of reported data from 0–3 year age group and 4–5 year age group weighted by the incidence of RVGE in these age groups [47, 53] | |
Days staying at home for an outpatient-treated RVGE | 5.3 days | REVEAL study data for Germany [11] | |
Days staying at home for hospitalised RVGE | 5 days | Average length of hospital stay, REVEAL study data for Germany [26] | |
Vaccine costs per dose | 51 € | Rotarix® 10-dose package taking into account mandatory rebates [49] | |
Administration costs per dose | 6 € | Regional contracts (e.g. “Barmer GEK”) [54] |